Ovarian cancer immuno-reactive antigen domain containing 1 (OCIAD1), a key player in ovarian cancer cell adhesion

Gynecologic Oncology

Volumn 109, Issue 2, 2008, Pages 226-233

  Sengupta, Saubhik ^a   Michener, Chad M ^a   Escobar, Pedro ^a,b   Belinson, Jerome ^a   Ganapathi, Ram ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Lee Cancer Care   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Cell adhesion; LPA; Metastasis; OCIAD1; Ovarian cancer

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; COLLAGEN TYPE 1; LAMININ; LAMININ 10; LAMININ 11; LYSOPHOSPHATIDIC ACID; MEMBRANE PROTEIN; OVARIAN CANCER IMMUNOREACTIVE ANTIGEN DOMAIN CONTAINING 1 PROTEIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C;

ARTICLE; CANCER CELL CULTURE; CELL ADHESION; CELL MEMBRANE; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METASTASIS; MOLECULAR WEIGHT; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL ADHESION; CELL LINE, TUMOR; COLLAGEN TYPE I; DOWN-REGULATION; FEMALE; HUMANS; LAMININ; LYSOPHOSPHOLIPIDS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PACLITAXEL; PROTEIN ISOFORMS; UP-REGULATION;

EID: 43049089685     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.12.024     Document Type: Article

References (27)

1. Edwards B.K., Brown M.L., Wingo P.A., Howe H.L., Ward E., Ries L.A., et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97 (2005) 1407-1427
2. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30.
3. Amadori D., Sansoni E., and Amadori A. Ovarian cancer: natural history and metastatic pattern. Front Biosci 2 (1997) g8-g10
4. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334 (1996) 1-6
5. Xu Y., Gaudette D.C., Boynton J.D., Frankel A., Fang X.J., Sharma A., et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res 1 (1995) 1223-1232
6. Xu Y., Shen Z., Wiper D.W., Wu M., Morton R.E., Elson P., et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. Jama 280 (1998) 719-723
7. Sutphen R., Xu Y., Wilbanks G.D., Fiorica J., Grendys Jr. E.C., LaPolla J.P., et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev 13 (2004) 1185-1191
8. Ren J., Xiao Y.J., Singh L.S., Zhao X., Zhao Z., Feng L., et al. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res 66 (2006) 3006-3014
9. Sengupta S., Xiao Y.J., and Xu Y. A novel laminin-induced LPA autocrine loop in the migration of ovarian cancer cells. Faseb J 17 (2003) 1570-1572
10. Fishman D.A., Liu Y., Ellerbroek S.M., and Stack M.S. Lysophosphatidic acid promotes matrixmetalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res 61 (2001) 3194-3199
11. Contos J.J., Ishii I., and Chun J. Lysophosphatidic acid receptors. Mol Pharmacol 58 (2000) 1188-1196
12. Fukushima N., and Chun J. The LPA receptors. Prostaglandins 64 (2001) 21-32
13. Sengupta S., Kim K.S., Berk M.P., Oates R., Escobar P., Belinson J., et al. Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion. Oncogene 26 (2007) 2894-2901
14. Baudhuin L.M., Cristina K.L., Lu J., and Xu Y. Akt activation induced by lysophosphatidic acid and sphingosine-1-phosphate requires both mitogen-activated protein kinase kinase and p38 mitogen activated protein kinase and is cell-line specific. Mol Pharmacol 62 (2002) 660-671
15. Stahle M., Veit C., Bachfischer U., Schierling K., Skripczynski B., Hall A., et al. Mechanisms in LPA-induced tumor cell migration: critical role of phosphorylated ERK. J Cell Sci 116 (2003) 3835-3846
16. Fang X., Schummer M., Mao M., Yu S., Tabassam F.H., Swaby R., et al. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta 1582 (2002) 257-264
17. Kim K.S., Sengupta S., Berk M., Kwak Y.G., Escobar P.F., Belinson J., et al. Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo. Cancer Res 66 (2006) 7983-7990
18. Li H., Ye X., Mahanivong C., Bian D., Chun J., and Huang S. Signaling mechanisms responsible for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells. J Biol Chem 280 (2005) 10564-10571
19. Hu L., Zaloudek C., Mills G.B., Gray J., and Jaffe R.B. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 6 (2000) 880-886
20. Davidson B., Espina V., Steinberg S.M., Florenes V.A., Liotta L.A., Kristensen G.B., et al. Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. Clin Cancer Res 12 (2006) 791-799
21. Sheehan K.M., Calvert V.S., Kay E.W., Lu Y., Fishman D., Espina V., et al. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 4 (2005) 346-355
22. Luo L.Y., Soosaipillai A., and Diamandis E.P. Molecular cloning of a novel human gene on chromosome 4p11 by immunoscreening of an ovarian carcinoma cDNA library. Biochem Biophys Res Commun 280 (2001) 401-406
23. Mukhopadhyay A., Das D., and Inamdar M.S. Embryonic stem cell and tissue-specific expression of a novel conserved gene, asrij. Dev Dyn 227 (2003) 578-586
24. Im M.J., Riek R.P., and Graham R.M. A novel guanine nucleotide-binding protein coupled to the alpha 1-adrenergic receptor. II. Purification, characterization, and reconstitution. J Biol Chem 265 (1990) 18952-18960
25. Johnson S.W., Laub P.B., Beesley J.S., Ozols R.F., and Hamilton T.C. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res 57 (1997) 850-856
26. Bapat S.A., Mali A.M., Koppikar C.B., and Kurrey N.K. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 65 (2005) 3025-3029
27. Loubani O., and Hoskin D.W. Paclitaxel inhibits natural killer cell binding to target cells by downregulating adhesion molecule expression. Anticancer Res 25 (2005) 735-741